Navigation Links
Channel Medsystems Receives Health Canada Approval to Begin Clinical Evaluation of its Innovative Procedure for Heavy Menstrual Bleeding; Hires Mary Edwards as Senior Vice President, Clinical and Regulatory Affairs.
Date:11/11/2013

SAN FRANCISCO, Nov. 11, 2013 /PRNewswire/ -- Channel Medsystems has received investigational testing authorization from Health Canada to begin enrolling patients in the Cryoablation Feasibility Trial (CRYSTAL), a multi-site clinical trial designed to evaluate its innovative cryothermic treatment for heavy menstrual bleeding due to benign causes.  The CRYSTAL study is designed to evaluate the efficacy and tolerability of Channel Medsystems' in-office cryothermic procedure. The Company expects to enroll its first patient in November.

(Logo: http://photos.prnewswire.com/prnh/20131111/SF14418LOGO)

One in five women suffers from heavy menstrual bleeding, impacting both their health and quality of life. In the US, global endometrial ablation (GEA) is the most common procedure for treating heavy menstrual bleeding.   Existing GEA procedures are typically performed in a hospital or outpatient surgical center and often require general anesthesia or conscious sedation to reduce discomfort during treatment.   Recovery times and outcomes are often highly dependent on the technology used, the skill of the physician and the anesthesia regimen elected.

Channel Medsystems' cryothermic device was developed to provide patients suffering from heavy menstrual bleeding -- and the physicians who treat them -- the option of an effective, safe and well-tolerated treatment that can be easily incorporated into the physician's office practice.  The technology uses cryothermic energy that gynecologists have relied on for years to perform delicate procedures. The two-and-a-half minute treatment takes advantage of the analgesic effect of cold energy and early clinical results suggest that Channel's cryothermic procedure can be comfortably done with minimal anesthesia.

"Our mission is to develop procedures that are effective, safe and well-tolerated under minimal anesthesia.  We believe our innovative delivery of cryothermic energy provides an excellent platform to treat heavy menstrual bleeding and we are excited to validate this application in our CRYSTAL clinical trial. Ultimately, we believe our technology will accelerate the transition of GEA procedures into the office setting, which in turn should translate into significant cost reductions for the healthcare system," said Ric Cote, President and CEO of Channel Medsystems.

Channel Medsystems also announced it has hired Mary Edwards, one of the top clinical and regulatory experts in the field of women's health, to run its North American trial and to serve as the Company's Senior Vice President of Clinical and Regulatory Affairs.  "Throughout my career, I have been a passionate advocate for technologies and procedures that benefit women," said Ms. Edwards.  "Our technology couples the gentle and safe profile of cryothermic energy with an intelligent system that supports precision and ease of use.  I am excited to be in a position where I can help bring a much-needed innovation to women suffering with heavy menstrual bleeding."

About the Cryothermic Technology Platform: Channel Medsystems' novel cryothermic technology and streamlined delivery system were developed with feedback from leading clinicians and biomedical engineers at the healthcare incubator, Theranova. The technology integrates cryothermic energy and the user controls into a self-contained, hand held device, eliminating the need for a separate control unit or capital equipment. 

About Channel Medsystems:  Channel Medsystems is a venture-backed company that was founded to bring innovation to the delivery of women's healthcare. The Company strives to develop treatments to meet the unique needs of female patients and the high standards of their healthcare providers. Channel Medsystems is committed to ensuring that patients have access to high quality outcomes that can be delivered in the convenience and comfort of their healthcare provider's office. For more information, please visit www.channelmedsystems.com.

CAUTION: This device is available for investigational use in Canada.  It is not available for sale or investigational use in the United States.


'/>"/>
SOURCE Channel Medsystems
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. SoundConnect Launches Innovative Channel Partner Webinar Series
2. ReachMD Radio Joins Clear Channel’s iHeartRadio
3. Multichannel Pipettes Promotion Now Available at Pipette.com
4. Discovery Channel MythBuster Star Jaime Vendera First Person on Record to Break a Glass with His Voice Endorses UV-Aid by UV Technologies, LLC
5. New from Cole-Parmer: Ismatec Reglo Independent Channel Control Peristaltic Pump
6. SoundConnect Named Adobe Connect Channel Partner
7. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
8. ReachMD on XM Satellite Radio Moves to Channel 245 Effective May 9, 2013
9. ChanTest Introduces the CardioChannelGram™ and SaVety Assessment
10. NSG Announces New Quartz Micro Flow Channel
11. Amarantus Bioscience Launches Online Corporate Communication Channels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , ... February 10, 2016 , ... ... medicine, has announced a new agreement with Singapore-based Global Stem Cells Network (GSCN) ... the Philippines, Thailand and Singapore in the latest adipose and bone marrow therapies. ...
(Date:2/9/2016)... 9, 2016  Regenicin, Inc. (OTC Bulletin Board: ... the development and commercialization of regenerative cell therapies ... organs, recently reported the Company,s operating results for ... 2016. Lonza America , Inc. (the ... year in the process of consummating an agreement ...
(Date:2/9/2016)... King of Prussia, PA (PRWEB) , ... February 09, 2016 , ... ... Director, Business Development, Europe. Based in Paris, he will focus on acquiring new ... needs are being met. , “Fred brings to our European clients ...
(Date:2/9/2016)... 9, 2016  DNAtrix, a clinical stage, ... announced that its lead product, DNX-2401, has ... an orphan medicinal product for the treatment ... glioma, strikes approximately 25,000 people a year ... http://photos.prnewswire.com/prnh/20160208/330986LOGO --> http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
Breaking Biology Technology:
(Date:2/2/2016)... RESTON, Va. , Feb. 2, 2016 /PRNewswire/ ... contract award from the U.S. Army Research Office ... extend the range and sensitivity of the company,s ... DoD,s Past Accounting Mission and, more generally, defense-related ... its DNA phenotyping capabilities (predicting appearance and ancestry ...
(Date:2/1/2016)... Canada , February 1, 2016 ... technological advancements to drive global touchfree intuitive gesture control ... --> Rising sales of consumer electronics coupled ... gesture control market size through ... consumer electronics coupled with new technological advancements to drive ...
(Date:2/1/2016)... wallet ( www.wocketwallet.com ) announces the launch of a new video featuring ... Las Vegas , where Joey appeared at the Wocket booth ... , where Joey appeared at the Wocket booth to meet and ... at the Consumer Electronics Show (CES2016) in Las Vegas ... fans. --> --> The video ...
Breaking Biology News(10 mins):